ROCKVILLE, Md. -- Accelovance, Inc. (Accelovance), a global contract research organization (CRO) focusing in Oncology, Vaccines, and General Medicine clinical development is expanding its international presence with a new facility in Wales which is expected to create 70 new clinical research jobs. The expansion will be supported by business financed by the Welsh Government, enabling Accelovance to grow its global workforce over the next two years.
This move follows Accelovance's recent acquisition of Altair Clinical, Ltd. (now Accelovance Europe, Ltd.) in January and will complement existing offices in Russia and Israel. Accelovance Europe, Ltd.'s Managing Director, Nigel Trim, will oversee the Welsh office expansion planned for the Swansea area.
"This opportunity provided by the Welsh Government will allow us to shift our primary UK operations to Wales which provides a highly-talented scientific workforce to support the continued growth of Accelovance," said Jamie Oliver, PharmD, Executive Director for European and Asian Operations.
Economy Minister Edwina Hart said, "Wales is making a name for itself as a great location for businesses in the life sciences sector and gaining a reputation as a UK hotspot for pharmaceutical services. Accelovance is a most welcome addition to the sector, and its presence will enhance our reputation in this particular field. This is a great project for Wales and a significant investment. I am delighted to welcome Accelovance and the substantial number of highly-skilled, well-paid jobs it will create."
Steve Trevisan, Accelovance CEO added, "We are grateful for the Welsh Government's support and are excited about our new expansion in Wales. The assistance provided by the Welsh Government was critical in our decision to make Wales our UK home."
About Accelovance
Accelovance, Inc., headquartered in Rockville, MD, is an industry award-winning Contract Research Organization (CRO) focused primarily in Oncology, Vaccines, and General Medicine. As a clinical services provider to the pharmaceutical and biotechnology industries, Accelovance offers comprehensive clinical development services including management and implementation of Phase I-IV clinical trials and a Clinical Engagement Solution utilized for recruitment, post-marketing surveillance, and long-term survival follow-up. For more information, visit the company's Web site at www.accelovance.com.
Press Contact: Michael Keens, VP Business Development
240.238.4941
[email protected]
Twitter: @Accelovance